These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 22477481

  • 1. [Staging with 18F-FDG-PET/CT influences stage-specific survival in advanced non-small cell lung cancer (NSCLC)].
    Tönnies S, Bauer TT, Misch D, Boch C, Blum T, Bittner RC, Förster GJ, Kollmeier J.
    Pneumologie; 2012 Apr; 66(4):212-7. PubMed ID: 22477481
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
    Liao S, Penney BC, Zhang H, Suzuki K, Pu Y.
    Acad Radiol; 2012 Jan; 19(1):69-77. PubMed ID: 22142679
    [Abstract] [Full Text] [Related]

  • 3. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
    Hebel CB, Behrendt FF, Heinzel A, Krohn T, Mottaghy FM, Bauerschlag DO, Verburg FA.
    Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
    [Abstract] [Full Text] [Related]

  • 4. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
    Messa C, Ceresoli GL, Rizzo G, Artioli D, Cattaneo M, Castellone P, Gregorc V, Picchio M, Landoni C, Fazio F.
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
    [Abstract] [Full Text] [Related]

  • 5. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
    Billé A, Pelosi E, Skanjeti A, Arena V, Errico L, Borasio P, Mancini M, Ardissone F.
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
    [Abstract] [Full Text] [Related]

  • 6. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.
    Ohno Y, Koyama H, Onishi Y, Takenaka D, Nogami M, Yoshikawa T, Matsumoto S, Kotani Y, Sugimura K.
    Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889
    [Abstract] [Full Text] [Related]

  • 7. Baseline SUVmax at PET-CT in stage IIIA non-small-cell lung cancer patients undergoing surgery after neoadjuvant therapy: prognostic implication focused on histopathologic subtypes.
    Lee HY, Lee KS, Park J, Han J, Kim BT, Kwon OJ, Ahn YC, Ahn MJ, Park K, Kim J, Shim YM.
    Acad Radiol; 2012 Apr; 19(4):440-5. PubMed ID: 22265854
    [Abstract] [Full Text] [Related]

  • 8. Diagnosis of recurrence and assessment of post-recurrence survival in patients with extracranial non-small cell lung cancer evaluated by 18F-FDG PET/CT.
    Jiménez-Bonilla JF, Quirce R, Martínez-Rodríguez I, Banzo I, Rubio-Vassallo AS, Del Castillo-Matos R, Ortega-Nava F, Martínez-Amador N, Ibáñez-Bravo S, Carril JM.
    Lung Cancer; 2013 Jul; 81(1):71-6. PubMed ID: 23597930
    [Abstract] [Full Text] [Related]

  • 9. Stage migration in planning PET/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer.
    Geiger GA, Kim MB, Xanthopoulos EP, Pryma DA, Grover S, Plastaras JP, Langer CJ, Simone CB, Rengan R.
    Clin Lung Cancer; 2014 Jan; 15(1):79-85. PubMed ID: 24238934
    [Abstract] [Full Text] [Related]

  • 10. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
    Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Scheiderbauer J, Budach W, Kotzerke J, Bares R.
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):54-9. PubMed ID: 16896660
    [Abstract] [Full Text] [Related]

  • 11. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
    Li M, Wu N, Liu Y, Zheng R, Liang Y, Zhang W, Zhao P.
    Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
    [Abstract] [Full Text] [Related]

  • 12. Brain metastasis in lung cancer. Comparison of cerebral MRI and 18F-FDG-PET/CT for diagnosis in the initial staging.
    Krüger S, Mottaghy FM, Buck AK, Maschke S, Kley H, Frechen D, Wibmer T, Reske SN, Pauls S.
    Nuklearmedizin; 2011 Aug; 50(3):101-6. PubMed ID: 21165538
    [Abstract] [Full Text] [Related]

  • 13. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [Abstract] [Full Text] [Related]

  • 14. Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? - From Chinese healthcare system perspective.
    Wang YT, Huang G.
    Eur J Radiol; 2012 Aug; 81(8):e903-9. PubMed ID: 22698711
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.
    Zaizen Y, Azuma K, Kurata S, Sadashima E, Hattori S, Sasada T, Imamura Y, Kaida H, Kawahara A, Kinoshita T, Ishibashi M, Hoshino T.
    Eur J Radiol; 2012 Dec; 81(12):4179-84. PubMed ID: 22884163
    [Abstract] [Full Text] [Related]

  • 16. Lymph node involvement in T1 non-small-cell lung cancer: could glucose uptake and maximal diameter be predictive criteria?
    Casiraghi M, Travaini LL, Maisonneuve P, Tessitore A, Brambilla D, Agoglia BG, Guarize J, Spaggiari L.
    Eur J Cardiothorac Surg; 2011 Apr; 39(4):e38-43. PubMed ID: 21242094
    [Abstract] [Full Text] [Related]

  • 17. 18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer.
    Mertens LS, Mir MC, Scott AM, Lee ST, Fioole-Bruining A, Vegt E, Vogel WV, Manecksha R, Bolton D, Davis ID, Horenblas S, van Rhijn BW, Lawrentschuk N.
    Urology; 2014 Feb; 83(2):393-8. PubMed ID: 24468513
    [Abstract] [Full Text] [Related]

  • 18. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
    Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH.
    J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
    [Abstract] [Full Text] [Related]

  • 19. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
    de Jong EE, van Elmpt W, Leijenaar RT, Hoekstra OS, Groen HJ, Smit EF, Boellaard R, van der Noort V, Troost EG, Lambin P, Dingemans AC.
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
    [Abstract] [Full Text] [Related]

  • 20. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N, Piperdi B, Garg MK, Bodner WR, Gucalp R, Perez-Soler R, Keller SM, Guha C.
    Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.